ITEK Inotek Pharmaceuticals Corporat

1.78
+0  (0%)
Previous Close 1.78
Open 1.75
Price To book 0.56
Market Cap 47.80M
Shares 26,930,000
Volume 1,272,278
Short Ratio 5.66
Av. Daily Volume 733,362

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 top-line data released January 3, 2017. Primary endpoint not met.
Trabodenoson
Primary open-angle glaucoma (POAG)
Phase 2 initiated July 2016. Data due 2H 2017.
Trabodenoson and latanoprost
Glaucoma

Latest News

  1. SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Inotek Pharmaceuticals Corporation (ITEK) and Lead Plaintiff Deadline: March 7, 2017
  2. SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Inotek Pharmaceuticals Corporation and Encourages Investors with Losses to Contact the Firm
  3. IMPORTANT INOTEK PHARMACEUTICALS CORPORATION INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the District of Massachusetts against Inotek Pharmaceuticals Corporati
  4. These 5 Stocks Under $10 Could Explode Higher Soon
  5. SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against TG Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
  6. SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Inotek Pharmaceuticals Corporation (ITEK) & Lead Plaintiff Deadline: March 7, 2017
  7. INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Inotek Pharmaceuticals Corporation and Encourages Investors with Losses to Contact the Firm
  8. SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Inotek Pharmaceuticals Corporation and Encourages Investors with Losses to Contact the Firm
  9. SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Inotek Pharmaceuticals Corporation (ITEK) & Lead Plaintiff Deadline: March 7, 2017
  10. INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Inotek Pharmaceuticals Corporation Investors
  11. ITEK SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Inotek Pharmaceuticals Corporation and a Lead Plaintiff Deadline of March 7, 2017
  12. IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Inotek Pharmaceuticals Corporation and Encourages Investors with Losses to Contact the Firm
  13. Robbins Arroyo LLP: Inotek Pharmaceuticals Corporation (ITEK) Misled Shareholders According to a Recently Filed Class Action
  14. Levi & Korsinsky Files Case in U.S District Court to Recover Losses Suffered By Investors In Inotek Pharmaceuticals (ITEK)
  15. Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Inotek Pharmaceuticals Corporation
  16. SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Inotek Pharmaceuticals Corporation To Contact The Firm Before Lead Plaintiff Deadline
  17. 4 Companies That Destroyed Shareholders Last Week
  18. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces It Has Filed a Class Action Lawsuit Against Inotek Pharmaceuticals Corporation and a Lead Plaintiff Deadline of March 7, 2017 – ITEK
  19. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Violations of Federal Securities Laws by Certain Officers and Directors of Inotek Pharmaceuticals Corporation
  20. Inotek Stock Hammered After Glaucoma Drug Failed